natgillin/translations-raw huggingface dataset:
The effect of Imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported Imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen. 
Vpliv zdravljenja z zdravilom Imatinib Accord na preživetje v kronični fazi pri novo diagnosticirani KML so nadalje preiskovali z retrospektivno analizo zgoraj opisanih podatkov o zdravilu Imatinib Accord skupaj s prvotnimi podatki druge študije faze III, v kateri so uporabljali IFN+Ara-C s povsem enakim režimom zdravljenja (n=325).
Imatinib Accord may cause your body to retain water (severe fluid retention). 
Zaradi zdravila Imatinib Accord lahko telo zadržuje vodo (lahko pride do močnega zastajanja tekočine).
of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). 
81 % odmerka odstranilo iz telesa v 7 dneh z blatom (68 % odmerka) in urinom (13 % odmerka).
The plasma AUC for this metabolite was found to be only 16% of the AUC for imatinib. 
Ugotovili so, da je plazemska AUC tega presnovka samo 16 % AUC imatiniba.
Chronic phase CML, MDS/MPD (starting dose 400 mg) HES/CEL (at dose 400 mg) 
kronična faza KML, MDS/MPD (začetni odmerek 400 mg) HES/CEL (pri odmerku 400 mg)
Imatinib Accord may do the same to some other medicines. 
Zdravilo Imatinib Accord lahko enako vpliva na druga zdravila.
The degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on Imatinib. 
Stopnja citogenetičnega in molekularnega odziva ima nedvomen učinek na dolgoročni izid pri bolnikih, zdravljenih z zdravilom Imatinib Accord.
Study 0102 38-month data Myeloid blast crisis (n=260) 
Študija 0102 podatki pri 38 mesecih mieloidna blastna kriza (n=260)
Study AJP01 Induction therapy 
Študija AJP01 indukcijsko zdravljenje
Dosing for children and adolescents should be on the basis of body surface area (mg/m2). 
Odmerjanje pri KML pri otrocih in mladostnikih Odmerjanje za otroke in mladostnike mora temeljiti na telesni površini (mg/m2).
At 84 months the estimated overall survival is 86.4% (83, 90) vs. 83.3% (80, 87) in the randomised Imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test). 
Po 84 mesecih je ocenjeno celotno preživetje v skupini randomizirani na zdravilo Imatinib Accord 86,4 % (83, 90) v primerjavi z 83,3 % (80, 87) v skupini randomizirani na IFN+Ara-C (p=0,073, test log-rank).
Imatinib Accord is also a treatment for children and adolescents with CML. 
Zdravilo Imatinib Accord je namenjeno tudi zdravljenju otrok in mladostnikov s KML.
In this retrospective analysis, the superiority of Imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) Imatinib patients and 63 (19.4%) IFN+Ara-C patients had died. 
V tej retrospektivni analizi se je z vidika celotnega preživetja zdravilo Imatinib Accord izkazalo za boljše od IFN+Ara-C (p<0,001): v 42 mesecih je umrlo 47 (8,5 %) bolnikov z zdravilom Imatinib Accord in 63 (19,4 %) bolnikov z IFN+Ara-C.
When given with a high-fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in Cmax and prolongation of tmax by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions. 
Če so imanitib dajali z zelo mastnim obrokom, se je obseg njegove absorpcije minimalno zmanjšal (Cmax se je zmanjšala za 11 %, tmax pa se je podaljšala za 1,5 ure), AUC pa se je v primerjavi z razmerami na tešče malo zmanjšala (7,4 %).
Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). 
Pri seštevku koncentracij imatiniba in njegovega presnovka je pri največji zaužiti količini materinega mleka na dan mogoče pričakoviti nizko skupno izpostavljenost dojenčka zdravilu in presnovku (~10 % terapevtskega odmerka).
- Patients who are concerned about their fertility while taking Imatinib Accord are advised to consult with their doctor. 
- Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Accord, naj se posvetujejo s svojim zdravnikom.
The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a 400 mg tablet) and stirred with a spoon. 
Predpisano število tablet je treba dati v primerno količino napitka (približno 50 ml za tableto po 100 mg in 200 ml za tableto po 400 mg) in premešati z žlico.
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). 
Imatinib je majhna molekula in je zaviralec protein-tirozin-kinaze, ki močno zavira aktivnost Bcr-Abl tirozin-kinaze, pa tudi nekaj receptorskih tirozin-kinaz: pri receptorju Kit, ki je receptor za dejavnik matičnih celic (stem cell factor, SCF), ki ga kodira protoonkogen c-Kit, pri receptorjih za diskoidinsko domeno (DDR1 in DDR2), pri receptorju za kolonije stimulirajoči faktor (CSF-1R) in pri receptorjih za rastni faktor iz trombocitov alfa in beta (platelet-derived growth factor PDGFR-alfa in PDGFRbeta).
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23% (90%CI [1.16-1.30]). 
Imatinib je v odmerku 400 mg dvakrat dnevno zaviral presnovo metoprolola s CYP2D6, tako da sta se Cmax in AUC metoprolola povečala za približno 23 % (90 % IZ [1,16-1,30]).
Imatinib Accord is a treatment for adults and children and adolescents for: 
Zdravilo Imatinib Accord je zdravilo za odrasle in otroke ter mladostnike:
The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia, or return to chronic phase CML using the same criteria as for the study in accelerated phase. 
Primarna učinkovitostna spremenljivka je bila stopnja hematološkega odziva, opisanega bodisi kot popolni hematološki odziv, kot odsotnost dokazov levkemije ali kot vrnitev v kronično fazo KML, pri čemer so uporabljali enaka merila kot pri študiji v pospešeni fazi.
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intratumoural haemorrhages were reported (see section 4.8). 
V študiji pri bolnikih z neresektabilnimi in/ali metastatskimi GIST so poročali tako o gastrointestinalnih kot o intratumorskih krvavitvah (glejte poglavje 4.8).
In paediatric CML patients the most frequent toxicities observed were grade3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia. 
Pri pediatričnih bolnikih s KML so izmed toksičnih učinkov najpogosteje opažali citopenije 3. ali 4. stopnje, ki vključuje nevtropenijo, trombocitopenijo in anemijo.
3) [95% CI] 
3) [95 %-ni interval zaupanja] delen
Haematological response Complete haematological response (CHR) No evidence of leukaemia 
Hematološki odziv popolni hematološki odziv (CHR) nobenih znakov levkemije (NEL)
Considering the limited safety database, the adverse events thus far reported in children and adolescents are consistent with the known safety profile in adult patients with Ph+ ALL. 
Baza podatkov do zdaj sporočenih neželenih dogodkov pri otrocih in mladostnikih je majhna, vendar se podatki v njej ujemajo z varnostnimi lastnostmi zdravila pri odraslih bolnikih s Ph+ ALL.
1800 to 3200 mg (as high as 3200 mg daily for 6 days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain. 
Odmerki od 1800 do 3200 mg (tudi do 3200 mg na dan 6 dni): oslabelost, mialgija, zvišana kreatinkinaza, zvišan bilirubin, bolečine v prebavilih.
Close monitoring of growth in children and adolescents under imatinib treatment is recommended (see section 4.8). 
Pri otrocih in mladostnikih, ki prejemajo imatinib, je priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
Total bilirubin: = 1.5 ULN AST: > ULN (can be normal or < ULN if total bilirubin is > ULN) 
AST: > IULN (lahko je normalna ali < IULN, če je celotni bilirubin > IULN)
• For Alu/Alu blisters This medicine does not require any special storage conditions. 
• Za pretisne omote iz aluminija/aluminija • Za shranjevanje tega zdravila niso potrebna posebna navodila.
A total of 71 (12.8%) and 85 (15.4%) patients died in the Imatinib and IFN+Ara-C groups, respectively. 
Skupno je umrlo 71 (12,8 %) bolnikov iz skupine z zdravilom Imatinib Accord in 85 (15,4 %) iz skupine z IFN+Ara-C.
Other medicines and Imatinib Accord 
Druga zdravila in zdravilo Imatinib Accord
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients. 
Spojina selektivno zavira proliferacijo in inducira apoptozo pri Bcr-Abl pozitivnih celičnih linijah, pa tudi pri svežih limfatičnih celicah bolnikov s KML, s prisotnim kromosomom Philadelphia, in z akutno limfoblastno levkemijo (ALL).
The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr-abl translocation)-positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z imatinibom za vse skupine pediatrične populacije s kronično mieloično levkemijo s prisotnim kromosomom Philadelphia (s translokacijo bcr-abl) (za podatke o uporabi pri pediatrični populaciji glejte poglavje
The median duration of second-line treatment with Imatinib was 64 months. 
Mediano trajanje zdravljenja z zdravilom Imatinib Accord kot zdravilom drugega izbora je bilo 64 mesecev.
There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib. 
V obdobju trženja zdravila so poročali o spontanih splavih in prirojenih nepravilnostih pri dojenčkih mater, ki so med nosečnostjo prejemale zdravilo imatiniba.
At a dose of 60 mg/kg, female rats had significant post-implantation foetal loss and a reduced number of live foetuses. 
Pri odmerku 60 mg/kg je prišlo pri samicah do znatne izgube plodov po vgnezditvi in do zmanjšanja števila živih plodov.
Table 4 Chemotherapy regimen used in combination with imatinib 
Preglednica 4 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom
BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for Imatinib Accord (see section 4.8). 
Zaviralce tirozin kinaze BCR-ABL povezujejo z razvojem trombotične mikroangiopatije, o posameznih primerih so poročali tudi pri uporabi zdravila Imatinib Accord (glejte poglavje 4.8).
With 7 years follow-up, there were 93 (16.8%) progression events in the Imatinib arm: 37 (6.7%) involving progression to accelerated phase/blast crisis, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC, and 10 (1.8%) CML unrelated deaths. 
Po 7 letih spremljanja je bilo v kraku z zdravilom Imatinib Accord 93 (16,8 %) dogodkov, ki pomenijo napredovanje bolezni: 37 (6,7 %) jih je vključevalo napredovanje v pospešeno fazo/blastno krizo, 31 (5,6 %) izgubo pomembnega citogenetičnega odziva, 15 (2,7 %) izgubo popolnega hematološkega odziva ali zvišanje WBC, 10 (1,8 %) pa je bilo smrti brez povezave s KML.
Dosing in children and adolescents at 260 and 340 mg/m2/day achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients. 
Odmerek 260 oziroma 340 mg/m2 pri otrocih in mladostnikih je dosegel enako izpostavljenost kot odmerek 400 mg oziroma 600 mg pri odraslih bolnikih.
Maximal plasma concentrations of imatinib in patients are 2-4 µmol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5-mediated metabolism of co-administered drugs is possible. 
Največje koncentracije imatiniba v plazmi bolnikov so 2-4 μmol/l, zato je možna inhibicija sočasno uporabljanih zdravil,katerih presnova poteka preko CYP2D6 in/ali CYP3A4/5.
VCR 1 mg i.v., days 7, 14; 
VCR 1 mg i.v., 7. in 14. dan;
10 film-coated tablets 30 film-coated tablets 90 film-coated tablets 30x1 film-coated tablets 60x1 film-coated tablets 90x1 film-coated tablets 
10 filmsko obloženih tablet 30 filmsko obloženih tablet 90 filmsko obloženih tablet 30 x 1 filmsko obložena tableta 60 x 1 filmsko obložena tableta 90 x 1 filmsko obložena tableta
If laboratory or clinical findings associated with TMA occur in a patient receiving Imatinib Accord, treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and anti-ADAMTS13antibody determination, should be completed. 
Če se pri bolniku, ki prejema zdravilo Imatinib Accord, pojavijo laboratorijski ali klinični znaki trombotične mikroangiopatije, je treba zdravljenje prekiniti in izvesti temeljito oceno pojava trombotične mikroangiopatije, vključno z aktivnostjo ADAMTS13 in določanjem protiteles proti ADAMTS13.
Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with imatinib. 
Bolnikom je treba razložiti, da lahko med zdravljenjem z imatinibom doživijo neželene učinke, na primer omotico, meglen vid ali zaspanost.
If you are being treated for DFSP 
- Če se zdravite zaradi DFSP
- If you forget a dose, take it as soon as you remember. 
Če ste pozabili vzeti zdravilo Imatinib Accord - Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
10 Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients. 
10 Mišično-skeletne bolečine in z njimi povezane dogodke so pogosteje opažali pri bolnikih s KML kot pri bolnikih z GIST.
20 film-coated tablets 60 film-coated tablets 120 film-coated tablets 180 film-coated tablets 30x1 film-coated tablets 60x1 film-coated tablets 90x1 film-coated tablets 120x1 film-coated tablets 180x1 film-coated tablets 
20 filmsko obloženih tablet 60 filmsko obloženih tablet 120 filmsko obloženih tablet 180 filmsko obloženih tablet 30 x 1 filmsko obložena tableta 60 x 1 filmsko obložena tableta 90 x 1 filmsko obložena tableta 120 x 1 filmsko obložena tableta 180 x 1 filmsko obložena tableta
The estimated rate of progression-free survival at 84 months was 81.2% in the Imatinib arm and 60.6% in the control arm (p<0.001). 
Ocenjeni delež preživelih brez napredovanja bolezni pri 84 mesecih je bil 81,2 % na kraku z zdravilo Imatinib Accord in 60,6 % na kontrolnem kraku (p<0,001).
Continuous daily exposure to imatinib early in the course of treatment in combination with chemotherapy in cohort 5-patients (n=50) improved the 4-year event-free survival (EFS) compared to historical controls (n=120), who received standard chemotherapy without imatinib (69.6% vs. 31.6%, respectively). 
Pri bolnikih v 5. kohorti (n=50) je neprekinjena vsakodnevna izpostavljenost zdravilu imatinib zgodaj v poteku zdravljenja v kombinaciji s kemoterapijo povečala delež bolnikov s 4-letnim preživetjem brez dogodkov (EFS - event-free survival) v primerjavi z zgodovinskimi kontrolami (n=120), kjer so bolniki prejeli standardno kemoterapijo brez zdravila imatinib (69,6 % v primerjavi z 31,6 %).
If cytopenia is unrelated to leukaemia, reduce dose of Imatinib Accord to 260 mg/m2. 
Če citopenija ni povezana z levkemijo, zmanjšajte odmerek zdravila Imatinib Accord na 260 mg/m2.
In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001). 
V kontrolirani študiji (ADE10) imatiniba v primerjavi z indukcijo s kemoterapijo pri 55 bolnikih z novo odkrito boleznijo, ki so bili stari 55 let ali več, je imatinib kot edino zdravilo povzročil značilno večji delež bolnikov s popolnim hematološkim odzivom kot kemoterapija (96,3 % v primerjavi s 50 %; p=0,0001).
This will help protect you from stomach problems when taking Imatinib Accord. 
Tako boste laže preprečili težave z želodcem, do katerih lahko pride pri jemanju zdravila Imatinib Accord.
Your doctor may decide to increase the dose to 400 mg, to be taken as 4 tablets of 100 mg or one tablet of 400 mg once a day, depending on how you respond to treatment. 
Vaš zdravnik se lahko odloči za zvišanje odmerka na 400 mg, kar vzamete kot 4 tablete po 100 mg ali eno tableto po 400 mg enkrat na dan, odvisno od vašega odziva na zdravljenje.
The free drug clearance of imatinib is probably similar between renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for imatinib (see sections 4.2 and 4.4). 
Očistek nevezane učinkovine je pri imatinibu verjetno podoben pri bolnikih z okvaro ledvic in pri tistih z normalnim delovanjem ledvic, saj predstavlja izločanje skozi ledvice manj pomemben način izločanja za imatinib (glejte poglavji 4.2 in 4.4).
- Do not breast-feed during the treatment with Imatinib Accord. 
- Med zdravljenjem z zdravilom Imatinib Accord ne dojite.
In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2. 
V študiji toksičnih učinkov na razvoj mladičev so opažali vpliv na rast ter zakasnjeno odpiranje nožnice in ločevanje prepucija pri izpostavljenosti, ki ustreza približno 0,3 do 2-kratniku izpostavljenosti, do kakršne v povprečju pride pri otrocih, ki prejemajo najvišji priporočeni odmerek 340 mg/m2.
Of a panel of potential comedications (acetaminophen, aciclovir, allopurinol, amphotericin, cytarabine, erythromycin, fluconazole, hydroxyurea, norfloxacin, penicillin V) only erythromycin (IC50 50 μM) and fluconazole (IC50 118 μM) showed inhibition of imatinib metabolism which could have clinical relevance. 
Od skupine možnih zdravil za sočasno uporabo (paracetamol, aciklovir, alopurinol, amfotericin, citarabin, eritromicin, flukonazol, hidroksisečnina, norfloksacin, penicilin V) sta samo eritromicin (IC50 50 μM) in flukonazol (IC50 118 μM) pokazala inhibicijo presnove imatiniba, ki bi bila lahko klinično pomembna.
The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 1.2 times the daily exposure in children and adolescents (based on AUC) at 340 mg/m2/day. 
Adenome/karcinome ledvic, papilome sečnega mehurja in sečnice, adenokarcinome tankega črevesa, adenome obščitničnih žlez, benigne in maligne medularne tumorje nadlevičnih žlez in papilome/karcinome ne-žleznega dela želodca so opazili pri odmerku 60 mg/kg/dan, kar predstavlja približno 1,7 do 1-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan in 1,2-kratnik dnevne izpostavljenosti otrok in mladostnikov (na podlagi AUC) pri 340 mg/m2/dan.
Papilloma/carcinoma of the preputial/clitoral gland were noted from 30 mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 times the daily exposure in children and adolescents (based on AUC) at 340 mg/m2/day. 
Papilome/karcinome prepucijske/klitorisne žleze so opazili pri odmerkih od 30 mg/kg/dan naprej, kar predstavlja približno 0,5-kratnik oziroma 0,3-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan, in 0,4-kratnik dnevne izpostavljenosti otrok in mladostnikov (na podlagi AUC) pri 340 mg/m2/dan.
Studies on patients receiving Imatinib Accord and its effect on fertility and gametogenesis have not been performed. 
Pri ljudeh niso opravili študij z bolniki, ki prejemajo imatinib, da bi preučili vpliv zdravila na plodnost in na gametogenezo.
The total daily dose in children and adolescents must not exceed 800 mg with CML and 600 mg with Ph+ALL. 
Celotni dnevni odmerek pri otrocih in mladostnikih ne sme preseči 800 mg pri zdravljenju KML in 600 mg pri zdravljenju Ph pozitivne ALL.
In addition, mortality was observed in juvenile animals (around weaning phase) at approximately 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2. 
Pri mladih živalih (okrog obdobja odstavljanja) so opažali tudi povečano smrtnost pri približno 2-kratniku izpostavljenosti, do kakršne v povprečju pride pri otrocih, ki prejemajo najvišji priporočeni odmerek 340 mg/m2.
(0.5 h), days 7, 8, 14, 15; CP 500 mg/ m2 i.v. 
(0,5 ur), 7., 8., 14., 15. dan; CP 500 mg/m2 i.v.
Dose increases from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe nonleukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. 
Povečanje odmerka s 400 mg na 600 mg ali 800 mg pri bolnikih s kronično fazo bolezni ali s 600 mg na največ 800 mg (odmerjanih po 400 mg dvakrat na dan) pri bolnikih v pospešeni ali v blastni krizi lahko pride v poštev, če bolnik nima hude neželene reakcije na zdravilo in hude nevtropenije ali trombocitopenije, ki ni povezana z levkemijo, v sledečih okoliščinah: napredovanje bolezni (kadarkoli); odsotnost zadovoljivega hematološkega odziva po najmanj 3 mesecih zdravljenja; odsotnost citogenetičnega odziva po 12 mesecih zdravljenja; ali izguba že prej doseženega hematološkega in/ali citogenetičnega odziva.
Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59), respectively. 
Hematološki odzivi so ostali enaki mediano 49 mesecev (od 19 do 60), citogenetični odzivi pa 47 mesecev (od 16 do 59).
DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/ m2 i.v. 
DEX 40 mg/dan 1.-4. in 11.-14. dan, izmenjaje z MTX 1 g/m2 i.v.
Some medicines can interfere with the effect of Imatinib Accord when taken together. 
Nekatera zdravila lahko ob sočasnem jemanju vplivajo na delovanje zdravila Imatinib Accord.
• adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 
• odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR - platelet derived growth factor receptor);
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p<0.001; OS p<0.0001) in two studies (AJP01 and AUS01). 
V dveh študijah (AJP01 in AUS01) sta preživetje brez bolezni (DSFdisease-free survival) in celokupno preživetje (OS - overall survival) pogosto presegala 1 leto in sta bila daljša kot pri zgodovinskih kontrolah (DFS p<0,001; OS p<0,0001).
The paediatric patient received 400 mg/m2/daily, subsequently increased to 520 mg/m2/daily. 
Pediatrični bolniki so prejemali po 400 mg/m2/dan, kasneje pa zvečan odmerek 520 mg/m2/dan.